Clinical trials: Cephalalgia
Migraine, Medication Overuse Headache
A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache
Medication overuse headache (MOH) is a type of headache caused by excessive use of acute headache or migraine medications (medications used to treat a headache or migraine once it begins).
- Trial name
- RESOLUTION (NCT05452239)
- Testing
- Eptinezumab
- Where
- 76 sites in United States, Australia and 9 more
- Volunteers
- 608 people
- Sponsor
- H. Lundbeck A/S
Migraine
A Study to Learn About the Benefit of Rimegepant Versus Triptans in Migraine Buddy App Users.
The purpose of this study is to collect information of the US users from the Migraine Buddy app between 20 October 2023 and 20 May 2024.
- Trial name
- NCT06532357
- Where
- United States
- Volunteers
- 1,536 people
- Sponsor
- Pfizer
Migraine, With or Without Aura
Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine
This study will evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (50 and 100 mg) compared to placebo for the acute treatment of a single migraine attack.
- Trial name
- ACHIEVE I (NCT02828020)
- Testing
- Ubrogepant
- Where
- 90 sites in United States
- Volunteers
- 1,672 people
- Sponsor
- Allergan
Migraine
A Study Examining the Use of a Migraine Medicine in the Treatment of Two Migraine Attacks in Patients Who Have Increased Skin Sensitivity
This is a research study examining a migraine medicine dihydroergotamine mesylate (DHE-45).It will be used to treat two migraine attacks in subjects who have a history of skin sensitivity associated with their headaches.This skin…
- Trial name
- NCT00203268
- Testing
- dihydroergotamine mesylate
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Thomas Jefferson University
Migraine
Efficacy and Safety Study of Rimegepant for the Acute Treatment of Migraine in Japanese Subjects (Japan Only)
This study is being conducted to determine the appropriate dose of rimegepant in Japanese subjects, as well as to evaluate the efficacy, safety, and tolerability of rimegepant in Japanese subjects for the acute treatment of…
- Trial name
- NCT05399459
- Testing
- Rimegepant 25 MG, Rimegepant 75 MG
- Where
- 50 sites in Japan
- Volunteers
- 897 people
- Sponsor
- Pfizer
Migraine
A Study With Lu AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments
Researchers are trying to learn whether a drug called Lu AG09222 can help prevent migraine headaches for people who have not been helped by other treatments that are used to prevent migraines.
- Trial name
- NCT05133323
- Testing
- Lu AG09222
- Where
- 28 sites in United States, Czechia and 4 more
- Volunteers
- 237 people
- Sponsor
- H. Lundbeck A/S
Cluster Headache
An Open Label Study Using Consecutive Intravenous Depacon With Oral Depakote ER for the Treatment of Cluster Headaches.
The purpose of this study is to collect and evaluate information on the use of Depakote Extended Release (ER) and Depacon Intravenous (IV) in patients with cluster headaches.
- Trial name
- NCT00203242
- Testing
- Depacon IV and Depakote ER
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Thomas Jefferson University
Cyclic Vomiting Syndrome, Abdominal Migraine
Auricular Neurostimulation for Cyclic Vomiting Syndrome
This study evaluates the efficacy of auricular neurostimulation via an non-invasive percutaneous electrical nerve field stimulator in children and adults with cyclic vomiting syndrome.
- Trial name
- NCT03434652
- Testing
- Percutaneous neurostimulation
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Medical College of Wisconsin
Headache, Pregnancy Related
Acute Headache Treatment in Pregnancy: Occipital Nerve Block vs PO Acetaminophen With Caffeine
This is an open label randomized controlled trial evaluating response to bupivacaine occipital nerve block compared to Tylenol/Caffeine cocktail in treatment of pregnant patients seeking care of headache.
- Conditions
- Headache, Pregnancy Related, Occipital Nerve Block
- Trial name
- NCT03951649
- Testing
- Occipital Nerve Block
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Cluster Headache
Non-invasive Neurostimulation of the Vagus Nerve for the Treatment of Cluster Headache
Multi-center, prospective, double-blind, randomized, sham-controlled pivotal study of non-invasive vagus nerve stimulation with the GammaCore® device for the acute treatment of cluster headache.
- Trial name
- CH (NCT01792817)
- Testing
- GammaCore
- Where
- 20 sites in United States
- Volunteers
- 150 people
- Sponsor
- ElectroCore INC
Migraine Disorders
Biomarker Study in Participants With Migraine
This is a study of participants with a diagnosis of migraine who completed another clinical trial NCT02163993. The participants received either LY2951742 or placebo.
- Trial name
- NCT02766517
- Testing
- Capsaicin
- Where
- 14 sites in United States
- Volunteers
- 37 people
- Sponsor
- Eli Lilly and Company
Hypertension, Heart Failure
LSFG-SKIN, Laser Speckle Flowgraphy
The purpose of this project is to quantify normal and abnormal skin blood flow regionally in different areas of the body(face, extremities, over burns and wounds) at baseline and over time in response to treatment or…
- Conditions
- Hypertension, Heart Failure, Vascular Ischemia, Burns
- Trial name
- NCT03660618
- Testing
- laser speckle flowgraphy
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Randy Kardon
Tension-Type Headache
Safety and Efficacy Study of TNX-201 Capsules for Treatment of Single Tension-Type Headache
This is a randomized, multicenter, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of a single dose of TNX-201 (140 mg) for the treatment of a single qualifying Tension-Type-Headache…
- Trial name
- NCT02423408
- Testing
- TNX-201
- Where
- 10 sites in United States
- Volunteers
- 165 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
Episodic Migraine
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound (International Classification of Headache Disorders, 2018).
- Trial name
- NCT05028569
- Testing
- BOTOX
- Where
- 133 sites in United States, Canada and 7 more
- Volunteers
- 775 people
- Sponsor
- AbbVie
Pain, Migraine
Efficacy and Safety of Acetaminophen, Aspirin and Caffeine With Sumatriptan in the Acute Treatment of Migraine
The main purpose of this study is to compare the efficacy and safety of aspirin, acetaminophen and caffeine (AAC) with sumatriptan and placebo in the acute treatment of migraine.
- Trial name
- NCT01248468
- Testing
- Aspirin, acetaminophen and caffeine, Sumatriptan
- Where
- 20 sites in United States
- Volunteers
- 752 people
- Sponsor
- Novartis
Migraine
A Safety and Efficacy Study to Evaluate AMG 334 in Migraine Prevention
Randomized, double-blind, placebo-controlled, parallel-group, multicenter study followed by an open-label treatment phase (OLTP).
- Trial name
- NCT02630459
- Testing
- Erenumab
- Where
- 44 sites in Japan
- Volunteers
- 475 people
- Sponsor
- Amgen
Migraine
A Dose-Finding Study of MK0974 in Acute Migraine (MK0974-004)
The purpose of this study is to investigate the efficacy and safety of an MK 0974 for migraine headache and to identify an appropriate dose range for further study.
- Trial name
- NCT00246337
- Testing
- MK0974, Rizatriptan
- Volunteers
- 420 people
- Sponsor
- Merck Sharp & Dohme LLC
Migraine
A Study to Evaluate the Efficacy and Safety of Eptinezumab for the Prevention of Migraine in Participants That Are Not Helped by Previous Preventive Treatments
Evaluation of eptinezumab in the prevention of migraine in participants with unsuccessful prior preventive treatments.
- Trial name
- DELIVER (NCT04418765)
- Testing
- Eptinezumab
- Where
- 138 sites in United States, Belgium and 15 more
- Volunteers
- 892 people
- Sponsor
- H. Lundbeck A/S
Intervention
A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache
This study will assess the efficacy of a neuromodulation device for the treatment of episodic migraine headache.
- Trial name
- NCT02991430
- Testing
- active neuromodulation for episodic migraine headache
- Where
- 10 sites in United States, United Kingdom
- Volunteers
- 45 people
- Sponsor
- Scion NeuroStim
Migraine
A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine
The purpose of this study is to assess the safety and efficacy of galcanezumab in people with treatment-resistant episodic or chronic migraine.
- Trial name
- CONQUER (NCT03559257)
- Testing
- Galcanezumab
- Where
- 69 sites in United States, Belgium and 11 more
- Volunteers
- 463 people
- Sponsor
- Eli Lilly and Company